You are here
Vertex and CRISPR Therapeutics AG to Co-Develop and Co-Commercialize CTX001 as CRISPR/Cas9 Gene Edited Treatment for Sickle Cell Disease and Beta Thalassemia
December 12, 2017
Today we announced that Vertex and CRISPR Therapeutics AG will co-develop and co-commercialize CTX001, an investigational gene editing treatment, as part of our previously annouced collaboration aimed at the discovery and development of new gene editing treatments that use the CRISPR/Cas9 technology. CTX001 represents the first gene-based treatment that Vertex exclusively licensed from CRISPR Therapeutics as part of the collaboration.